



University College Dublin,  
Belfield, Dublin 4, Ireland

[rio@ucd.ie](mailto:rio@ucd.ie)

An Coláiste Ollscoile, Baile Átha Cliath,  
Belfield, Baile Átha Cliath 4, Éire

[www.ucd.ie/researchintegrity/](http://www.ucd.ie/researchintegrity/)

19<sup>th</sup> December 2024

**PRIVATE AND CONFIDENTIAL**

By email

**Re: Allegation of Misconduct in Research –  
Outcome of Inquiry Panel**

To Whom It Concerns:

I refer to your email of 7<sup>th</sup> August 2024 regarding the allegation of misconduct in research in relation to the publication:

Caiazza, F., McGowan, P., Mullooly, M. *et al.* Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. *Br J Cancer* **112**, 1895–1903 (2015). <https://doi.org/10.1038/bjc.2015.163>

The allegation was processed in accordance with the UCD Procedure for the Investigation of Misconduct in Research (the “Procedure”).

Accordingly, as Research Integrity Officer of UCD, I carried out an initial review of the allegation, subsequent to which, an Inquiry Panel was convened. The role of the Inquiry Panel was to determine whether, in its reasonable opinion, clearly supported by the evidence, the allegations are sufficiently serious and have sufficient substance to justify the establishment of an Investigation Panel.

The Inquiry Panel has now completed its review and determined that “*we did not find sufficient evidence that would trigger formation of an 'official investigation of misconduct' panel*”.

In accordance with our Procedure, the process has now concluded as there is no evidence that would warrant the establishment of an Investigation Panel.

Yours sincerely,

Grace Mulcahy  
**Research Integrity Officer**  
University College Dublin